Adoptive T cell therapy with tumor infiltrating lymphocytes (TIL) has achieved impressive
clinical results with durable complete responses in patients with metastatic melanoma. The
TILs are isolated from patients own tumor tissue followed by in vitro expansion and
activation for around 4-6 weeks. Before TIL infusion the patients receive 1 week of
preconditioning chemotherapy with cyclophosphamide and fludarabine. After TIL infusion
Interleukin-2 is administered to support T cell acitivation and proliferation in vivo.
Recent studies suggest, that TIL therapy works in other cancers than Metastatic Melanoma,
including Ovarian Cancer. In this study TIL therapy is administered to patients with
metastatic Ovarian Cancer.